ProMIS Neurosciences announced it has received fast track designation from the U.S. FDA for PMN310, its investigational antibody therapy for Alzheimer’s disease, according to the company.
PMN310 is designed to selectively target toxic amyloid-beta oligomers, which the company claims are a primary driver of neurodegeneration in Alzheimer’s disease. By focusing on these specific oligomers rather than all amyloid-beta forms, ProMIS Neurosciences said its approach aims to reduce off-target effects and improve safety.
The company is currently advancing PMN310 through a Phase 1a clinical trial evaluating safety, tolerability and pharmacokinetics in healthy volunteers. According to the company, the fast track designation could enable more frequent interactions with the FDA and potential eligibility for accelerated approval or priority review, supporting faster development and review of PMN310.
ProMIS Neurosciences claims PMN310’s design differentiates it from earlier antibody therapies by selectively binding to disease-related oligomers, sparing monomers and plaque forms that may have physiological roles.
The company said it remains committed to advancing PMN310 as part of its broader pipeline targeting neurodegenerative diseases characterized by toxic protein aggregates.
ProMIS Neurosciences is headquartered in Toronto, Canada, and focuses on developing antibody therapies aimed at selectively neutralizing toxic misfolded proteins associated with neurodegenerative disorders.
